🔴 Cue Biopharma is trading 2% down in pre-market as broader market weakness pressures biotech shares

Cue Biopharma is trading 2% down at $31.10 as broader U.S. market weakness pressures risk-sensitive biotechnology shares.

• The Nasdaq Composite is down 0.86% pre-market, while Treasury yields remain elevated.
• No new company-specific announcement was identified for September 24, 2026.
• Positive CUE-221 Phase 2 results released September 20 had already driven substantial volatility.